You just read:

FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status

News provided by

GlaxoSmithKline plc

Apr 29, 2020, 16:13 ET